Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Amylyx Pharmaceuticals (AMLX) Profit After Tax: 2021-2024

Historic Profit After Tax for Amylyx Pharmaceuticals (AMLX) over the last 4 years, with Dec 2024 value amounting to -$301.7 million.

  • Amylyx Pharmaceuticals' Profit After Tax rose 52.70% to -$34.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$149.3 million, marking a year-over-year increase of 42.47%. This contributed to the annual value of -$301.7 million for FY2024, which is 712.42% down from last year.
  • As of FY2024, Amylyx Pharmaceuticals' Profit After Tax stood at -$301.7 million, which was down 712.42% from $49.3 million recorded in FY2023.
  • Amylyx Pharmaceuticals' Profit After Tax's 5-year high stood at $49.3 million during FY2023, with a 5-year trough of -$301.7 million in FY2024.
  • Over the past 3 years, Amylyx Pharmaceuticals' median Profit After Tax value was -$198.4 million (recorded in 2022), while the average stood at -$150.3 million.
  • In the last 5 years, Amylyx Pharmaceuticals' Profit After Tax skyrocketed by 124.84% in 2023 and then slumped by 712.42% in 2024.
  • Over the past 4 years, Amylyx Pharmaceuticals' Profit After Tax (Yearly) stood at -$87.9 million in 2021, then plummeted by 125.60% to -$198.4 million in 2022, then soared by 124.84% to $49.3 million in 2023, then slumped by 712.42% to -$301.7 million in 2024.